Peter Boström

Impact of asymptomatic bacteriuria on the outcomes and tolerability of Bacillus Calmette–Guérin immunotherapy (2026)

Scandinavian Journal of Urology

Nummi, Antti; Nurminen, Pertti; Kesti, Olli; Högerman, Mikael; Ettala, Otto; Boström, Peter J.; Kaipia, Antti; Sairanen, Jukka; Järvinen, Riikka

(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )

Can Radiomics Based Models Survive Across MRI Scanners? (2026)

Lecture Notes in Networks and Systems

Chaudhary, Jatin; Jambor, Ivan; Aronen, Hannu; Ettala, Otto; Saunavaara, Jani; Boström, Peter; Heikkonen, Jukka; Kanth, Rajeev; Merisaari, Harri

(A4 Vertaisarvioitu artikkeli konferenssijulkaisussa)

Radical cystectomy practice patterns in the Nordic countries: results from the prospective NorCys study (2026)

Scandinavian Journal of Urology

Venhomaa, Tiia; Nikulainen, Ilkka; Bobjer, Johannes; Bläckberg, Mats; Bro, Lasse; Brandt, Simone Buchardt; Ettala, Otto; Fabrin, Knud; Gudjonsson, Sigurdur; Haug, Erik Skaaheim; Högerman, Mikael; Hyldgaard, Josephine M.; Jerlström, Tomas; Kirrander, Peter; Koskinen, Ilmari; Lam, Gitte; Leskinen, Markku J.; Liedberg, Fredrik; Livbjerg, Astrid Helene; Seikkula, Heikki; Skovhus, Katharina; Ströck, Viveka; Tuckus, Grazvydas; Virta, Ville; Vrang, Marie-Louise; Jensen, Jørgen Bjerggaard; Boström, Peter J.

(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä)

Aberrantly glycosylated PSMA in urine as a potential marker for prostate cancer (2026)

Clinica Chimica Acta

Khan, Misba; Islam, Md. Khirul; Taimen, Pekka; Boström, Peter J.; Lamminmäki, Urpo; Leivo, Janne

(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )

Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: A Nationwide Analysis of Eligibility, Utilization, and Outcomes (2025)

Cancers

Nikulainen, Ilkka; Salminen, Antti P.; Högerman, Mikael; Seikkula, Heikki; Boström, Peter J.; The Finnish National Cystectomy Database Research Group

(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )

Cross-cultural adaptation and psychometric validation of the Finnish version of the Expanded Prostate Cancer Index Composite-26 for patients with localised prostate cancer (2025)

Scandinavian Journal of Urology

Ettala, Otto; Bergroth, Robin; Riikonen, Jarno; Boström, Peter; Koskimäki, Juha; Kuisma, Jani; Rannikko, Antti; Vaarala, Markku; Sanda, Martin G; Santti, Henrikki

(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )

Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic obstruction: 1-year clinical outcomes of a phase II study (2025)

BJU International

Viitala, Antti; Anttinen, Mikael; Mäkelä, Pietari; Pärssinen, Heikki; Nurminen, Pertti; Sainio, Teija; Saunavaara, Jani; Taimen, Pekka; Sequeiros, Roberto Blanco; Boström, Peter J.

(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )

Long‐Term Risk of Clinically Significant Prostate Cancer in Biopsy‐Negative Patients With Baseline Biparametric Prostate MRI (2025)

Journal of Magnetic Resonance Imaging

Parhiala, Laura; Knaapila, Juha; Jambor, Ivan; Verho, Janne; Syvänen, Kari; Aronen, Hannu; Boström, Peter; Ettala, Otto

(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )

Improved diagnostic performance of a phage display antibody-assisted intact free PSA assay as used in the four kallikrein concept applied to the IMPROD/multi-IMPROD study (2025)

Clinica Chimica Acta

Khan, Md. Ferdhos L.; Perez, Ileana M.; Kekki, Henna; Taimen, Pekka; Boström, Peter J.; Jambor, Ivan; Ettala, Otto; Pahikkala, Tapio; Pettersson, Kim

(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )

Time to abandon routine urine analysis prior to Bacillus Calmette–Guérin administration in asymptomatic patients (2025)

BJUI COMPASS

Nummi, Antti; Nurminen, Pertti; Kesti, Olli; Högerman, Mikael; Ettala, Otto; Boström, Peter J.; Kaipia, Antti; Sairanen, Jukka; Järvinen, Riikka

(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )

Peter

Boström

Contact

Links

Publications

Sort by:

Impact of asymptomatic bacteriuria on the outcomes and tolerability of Bacillus Calmette–Guérin immunotherapy (2026)

Can Radiomics Based Models Survive Across MRI Scanners? (2026)

Radical cystectomy practice patterns in the Nordic countries: results from the prospective NorCys study (2026)

Aberrantly glycosylated PSMA in urine as a potential marker for prostate cancer (2026)

Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer: A Nationwide Analysis of Eligibility, Utilization, and Outcomes (2025)

Cross-cultural adaptation and psychometric validation of the Finnish version of the Expanded Prostate Cancer Index Composite-26 for patients with localised prostate cancer (2025)

Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic obstruction: 1-year clinical outcomes of a phase II study (2025)

Long‐Term Risk of Clinically Significant Prostate Cancer in Biopsy‐Negative Patients With Baseline Biparametric Prostate MRI (2025)

Improved diagnostic performance of a phage display antibody-assisted intact free PSA assay as used in the four kallikrein concept applied to the IMPROD/multi-IMPROD study (2025)

Time to abandon routine urine analysis prior to Bacillus Calmette–Guérin administration in asymptomatic patients (2025)